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The proapoptotic PB1-F2 protein of influenza A viruses has been shown to contribute to pathogenesis in the mouse
model. Expression of full-length PB1-F2 increases the pathogenesis of the influenza A virus, causing weight loss, slower
viral clearance, and increased viral titers in the lungs. After comparing viruses from the Hong Kong 1997 H5N1
outbreak, one amino acid change (N66S) was found in the PB1-F2 sequence at position 66 that correlated with
pathogenicity. This same amino acid change (N66S) was also found in the PB1-F2 protein of the 1918 pandemic A/
Brevig Mission/18 virus. Two isogenic recombinant chimeric viruses were created with an influenza A/WSN/33 virus
background containing the PB1 segment from the HK/156/97: WH and WH N66S. In mice infected with WH N66S virus
there was increased pathogenicity as measured by weight loss and decreased survival, and a 100-fold increase in virus
replication when compared to mice infected with the WH virus. The 1918 pandemic strain A/Brevig Mission/18 was
reconstructed with a pathogenicity-reducing mutation in PB1-F2 (S66N). The resultant 1918 S66N virus was attenuated
in mice having a 3-log lower 50% lethal dose and caused less morbidity and mortality in mice than the wild-type virus.
Viral lung titers were also decreased in 1918 S66N–infected mice compared with wild-type 1918 virus–infected mice. In
addition, both viruses with an S at position 66 (WH N66S and wt 1918) induced elevated levels of cytokines in the lungs
of infected mice. Together, these data show that a single amino acid substitution in PB1-F2 can result in increased viral
pathogenicity and could be one of the factors contributing to the high lethality seen with the 1918 pandemic virus.
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increased virulence. PLoS Pathog 3(10): e141. doi:10.1371/journal.ppat.0030141
Introduction
Inﬂuenza A virus causes 300,000–500,000 deaths worldwide
each year, and in pandemic years, this number can increase to
1 million (in 1957–1958 ) or as high as 50 million, as was seen
in 1918–1919 [1–3]. More recently, H5N1 highly pathogenic
avian inﬂuenza viruses have generated great concern regard-
ing their potential to cause a pandemic. H5N1 infections in
humans were seen in Hong Kong in a small outbreak in 1997
that resulted in 18 human infections and six fatalities, and
since 2003, 309 human cases of H5N1 have been conﬁrmed
with a 61% fatality rate (6/1/07) [4–7]. Recent work on these
viruses has aimed to elucidate the virulence factors that
account for the severe illness observed in humans and mice
[4,8–12].
The viral PB1 segment is of particular interest, since, in
addition to the glycoprotein genes, the PB1 gene was the only
other segment that was exchanged in the pandemic viruses of
1957 and 1968 [13]. Introduction of a novel PB1 gene into the
1998 swine reassortant viruses further implicates the role of
this gene in the pathogenesis of (animal) inﬂuenza [14].
Moreover, while changes in the surface glycoproteins allow
the viruses to overcome the preexisting humoral immune
response, they may not be solely responsible for the high
virulence of the pandemic inﬂuenza viruses. In particular, the
1918 pandemic was associated with signiﬁcantly higher
morbidity and mortality than the subsequent pandemics
[15]. Recent reconstruction of the 1918 virus has conﬁrmed
that the viral polymerase from the 1918 inﬂuenza virus is
required for full pathogenicity of the recombinant 1918 virus
in mice [16]. In fact, substitution of the viral polymerase
genomic segments with those of the modern H1N1 strain
severely attenuated the virus in mice [16]. Recent identiﬁca-
tion and characterization of a novel inﬂuenza virus protein
called PB1-F2 encoded by the PB1 gene introduced a
potential virulence factor that could play a role in patho-
genesis of infection with pandemic inﬂuenza viruses and
explain the selection of the PB1 gene in these viruses [17].
The inﬂuenza virus PB1-F2 is a 90–amino acid (aa) protein
that is associated with the induction of cell death. The protein
directly permeabilizes mitochondria, resulting in the dis-
sipation of the mitochondrial membrane potential and the
release of cytochrome c [17–19]. We have previously shown
that PB1-F2 contributes to viral pathogenesis in the mouse
model and wanted to further investigate whether the PB1-F2
proteins encoded by highly pathogenic viruses have con-
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pathogenicity [20]. We chose to study the PB1-F2 proteins of
the Hong Kong 1997 H5N1 viruses that caused an outbreak in
humans. Characterization of the isolated viruses in mice
revealed that the viruses could be subdivided into three
different groups based on the pathogenicity phenotype: high-
virulence, intermediate-virulence, and low-virulence [21].
Further studies provided molecular correlates of pathoge-
nicity in the high-virulence group, though such studies were
not conducted for the PB1-F2 protein [22].
Herein, we assess the contribution of the PB1-F2 protein to
the pathogenicity of a highly pathogenic H5N1 virus and the
1918 pandemic strain virus. An alignment of the aa sequences
of isolates from the Hong Kong 1997 H5N1 outbreak revealed
that a mutation, N66S, was associated with high pathogenicity
phenotype in mice. Using a recombinant A/WSN/33 virus with
the PB1 segment of A/HK/156/97, we observed increased
morbidity and mortality of mice infected with a virus that
contained the N66S mutation. In addition, infection with the
reconstructed A/Brevig Mission/18 virus, which has an S at
position 66, resulted in increased pathogenicity when
compared with a reconstructed A/Brevig Mission/18 virus in
which position 66 was changed to N [16]. We thereby show
that PB1-F2 proteins from highly virulent viruses can
contribute to pathogenicity, and identify a single aa change
that confers a virulent phenotype in mice.
Materials and Methods
Cell Lines
Madin Darby canine kidney (MDCK), 293T, and A549 cells
were obtained from ATCC (http://www.atcc.org/) and were
maintained in MEM and DMEM culture media (Gibco, http://
www.invitrogen.com/), respectively, supplemented with 10%
fetal calf serum (Hyclone, http://www.hyclone.com/) and
penicillin/streptomycin (Gibco).
Constructs and Cloning
The pPolI vectors encoding viral genomic RNA of the WSN
strain have been described previously [23]. The PB1 gene of
the A/HK/156/97 virus was reverse transcribed from puriﬁed
genomic RNA, ampliﬁed by PCR with PB1 segment-speciﬁc
primers, and cloned into the pPolI vector. The cloning of
genes for A/Brevig Mission/18 has been described previously
[16]. To generate pPolI vectors encoding the N66S PB1-F2
mutants, the pPolI vectors encoding the A/HK/483/97 PB1 or
A/Brevig Mission/18 PB1 were subjected to site-directed
mutagenesis using the Stratagene Quick-Change mutagenesis
kit (Stratagene, http://www.stratagene.com/). Sequences of
each construct were conﬁrmed by automated sequencing
performed at the Mount Sinai sequencing core facility.
Reverse Genetics for Recombinant Viruses
The reverse genetics technique for the generation of
recombinant inﬂuenza viruses has been described previously
[23]. Brieﬂy, 293T cells were transfected with eight pPolI
vectors encoding the viral genomic RNA segments and four
pCAGGS protein expression vectors encoding the subunits of
viral polymerase and the nucleocapsid protein. The trans-
fected 293T cells were cocultured with MDCK cells, and virus
released into the supernatant was isolated by plaque
puriﬁcation on MDCK cells. The presence of the introduced
mutations was conﬁrmed by reverse transcription and
sequencing of the PB1 genes of the newly generated viruses.
Viruses possessing 1918 genes were generated under biosafety
level 3 (BSL-3 with enhancements) containment [24] to
ensure the safety of laboratory workers, the environment,
and the public. All subsequent laboratory and animal work
with live virus containing A/Brevig Mission/18 genes also was
performed under these high-containment conditions.
Mouse Experiments
Female C57/BL6 mice 6 to 7 wk old (Jackson Laboratories,
http://www.jax.org/) were anesthetized with intraperitoneal
injection of 0.07 ml of ketamine/xylazine (0.15 mg ketamine
and 0.03 mg xylazine), and infectious virus was diluted in PBS/
BSA/PS (phosphate-buffered saline/bovine serum albumin/
penicillin and streptomycin) and inoculated intranasally in a
volume of 30 ll. To assess virus pathogenicity, groups of four
mice were inoculated with appropriate dose and were
monitored daily for weight loss over 8 d. Mice that lost more
than 25% of their initial body weight were killed according to
institutional guidelines and scored as dead. To determine
viral replication in the lungs, lungs were collected on days 1,
2, 3, 5, 7, and 8 after infection from 2 (days 1 and 2) or 4 (days
3, 5, 7, and 8) mice from each group and two mice in the PBS
group. The lungs were homogenized in PBS using a Dounce
homogenizer and processed for virus titering. Virus titers in
the supernatant of lung homogenates were determined by
plaque assay in MDCK cells.
For 1918 recombinant virus infections, female BALB/c
mice, 6 to 7 wk old (Jackson Laboratories) were anesthetized
with an intraperitoneal injection of 0.2 ml of 2,2,2-tribro-
moethanal in tert-amylalcohol (Avertin; Aldrich Chemical
Co., http://www.sigmaaldrich.com/), and 50 ul of infectious
virus diluted in PBS was inoculated intranasally. The 50%
lethal dose (LD50) titers were determined by inoculating
groups of three mice intranasally with serial 10-fold dilutions
of virus. LD50 titers were calculated by the method of Reed
and Muench [25]. Individual body weights from eight mice
were recorded for each group daily and monitored daily for
disease signs and death for 14 d after infection. For
determination of lung virus titers, 18 additional mice were
infected intranasally with the intermediate inoculating dose
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Author Summary
PB1-F2 is the most recently discovered protein produced by the
influenza A virus. It has been previously shown that PB1-F2 is
present in the mitochondria, where it induces cell death; our
laboratory has demonstrated that PB1-F2 is a contributor to
pathogenesis in the mouse model of infection. To study PB1-F2
further, we examined highly pathogenic strains of avian influenza
virus and located an amino acid change that seemed to be
associated with increased death in mice. We studied this amino acid
change in PB1-F2 at position 66 in two different viruses. A
recombinant virus that has a PB1 gene from an H5N1 virus was
used as well as a fully reconstructed 1918 pandemic virus. In this
study, we show that a mutation in PB1-F2 found in highly
pathogenic influenza A virus isolates causes nonpathogenic viruses
to induce disease in mice. In addition, we show that the increased
pathogenicity is associated with higher levels of virus and cytokines
in the lungs. We conclude that PB1-F2 does affect pathogenicity,
and that position 66 seems to play an important role in contributing
to the effects of PB1-F2 in the mouse model.(10
4 plaque-forming unit [PFU]) of virus. On days 1–3 and 5–8
after infection, three mice from each group were killed, and
whole lungs were removed aseptically and homogenized in 1
ml of sterile PBS. Homogenates were titrated for virus
infectivity using a standard plaque assay. The statistical
signiﬁcance of virus titer data was determined by using
analysis of variance.
Cytokine Quantitation
To determine the in vivo levels of cytokine supernatants
from the lung, homogenates of the lungs of WH-infected mice
were assayed for IFN-c and TNF-a (assay sensitivity, 2 pg/ml)
by use of enzyme-linked immunosorbent assay kits purchased
from R&D Systems (http://www.rndsystems.com/).
For high-containment laboratory work with 1918 recombi-
nant viruses, the in vivo levels of cytokine proteins were
determined from three individual mice per group. On day 4
after infection, mice were exsanguinated from the axilla and
killed, and lung tissues were removed from naive and infected
mice. Individual whole-lung samples were immediately frozen
at  70 8C. On the day of analysis, tissues were thawed,
homogenized in 1 ml of cold PBS, and centrifuged at 150g for
5 min. Cytokine protein levels were measured from clariﬁed
lung homogenates by the Bioplex Protein Array system [26]
(Bio-Rad, http://www.bio-rad.com/) using beads speciﬁc for
mouse IL-1b, IFN-c, and TNFa. Cytokine protein levels were
measured according to the manufacturer’s instructions by
ﬂuorescently conjugated monoclonal antibodies in duplicate
against a standard curve.
Results
Conserved Mutations in Highly Pathogenic Influenza A
Viruses
It has been previously shown that H5N1 viruses from the
Hong Kong 1997 outbreak fall into three separate pathoge-
nicity phenotypes: low, intermediate, and high [22]. The
intermediate phenotype had aa sequence identity with the
high-pathogenicity phenotype and all of the previously
identiﬁed molecular correlates of a high pathogenicity
phenotype, but caused a less severe disease in mice. However,
PB1-F2 was not examined in the study by Katz et al. because it
was not known at the time [22]. Alignment of the 1997 human
H5N1 PB1-F2 sequences available in the National Center for
Biotechnology Information database (http://www.ncbi.nlm.
nih.gov/) revealed several aa changes that separated the
high-virulence from the low-virulence groups. These were
(low-virulence versus high-virulence) E6D, R53K, N66S, and
R75H. These changes were silent in the open reading frame of
the PB1 gene. Alignment of the proteins with other PB1-F2
sequences available in the database revealed that with the
exception of the N66S substitution, all of the described
mutations were previously present in other inﬂuenza viral
strains. The N66S mutation was of a particular interest, since
it was found only to be present in the highly virulent 1997
H5N1 group, in the PB1-F2 proteins of some avian isolates,
and in the 1918 A/Brevig Mission/18 PB1-F2 (Figure 1).
Interestingly, the A/HK/156/97 virus (from the intermediate-
virulence group), which was previously shown to possess all of
the molecular signatures of the high-virulence group,
possesses N at position 66 of the PB1-F2 protein.
aa residue 66 resides in the C-terminal a-helical region of
PB1-F2. This region is the interacting domain for ANT3 and
VDAC1 and contains the mitochondrial targeting sequence,
making the C-terminal region essential for the function of
PB1-F2 [19,27]. The location of the N66S mutation in the
structure of PB1-F2 and its presence in the C-terminal region
supports the hypothesis that this aa change could impact
PB1-F29s effects in vivo. We hypothesized that this aa
substitution may be responsible for the decreased pathoge-
nicity phenotype observed for the A/HK/156/97 virus. Given
these ﬁndings, we proceeded to determine whether the PB1-
F2 mutation in position 66 (N66S) in the 1997 H5N1 viruses
contributed to viral pathogenicity.
Impact of PB1-F2 aa 66 on Viral Growth and Virulence In
Vitro and In Vivo
In vitro. To examine the effect of the mutation in position
66 on the pathogenicity of inﬂuenza A viruses, we created
recombinant viruses containing either an asparagine (N) or
Figure 1. Alignment and Location of N66S Mutation in the PB1-F2 Protein
Alignment of human isolates of influenza A viruses from a H5N1 Hong Kong outbreak and from the 1918 H1N1 pandemic. Viruses in red are of the high-
pathogenic phenotype, those in purple are of intermediate pathogenicity, and those in blue are of low pathogenicity in mice. Yellow indicates C-
terminal region with a-helical structure, and green indicates the minimal mitochondrial targeting sequence.
doi:10.1371/journal.ppat.0030141.g001
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Mutation in PB1-F2 Increases Virulenceserine (S) at that site of the PB1-F2 protein. A chimeric virus
was created in the A/WSN/33 background that contained the
A/HK/156/97 PB1 gene (WH). These viruses were rescued in a
BSL-2 environment, making them easier to study. In addition,
the WH virus has been characterized in a previous paper [20].
Site-directed mutagenesis was used to introduce the N66S
mutation in PB1-F2 without changing the amino acid
sequence of the PB1 protein (WH N66S). These viruses were
then grown in MDCK cells to determine their growth kinetics
in vitro. Cells were inoculated at two different multiplicities
of infection (MOIs), 0.1 and 0.001. The two viruses have
similar replication kinetics in MDCK cells (Figure 2A). The
r1918 and r1918 S66N viruses also have similar growth
kinetics in MDCK cells when inoculated at MOIs of .01 and
.001 (Figure 2B).
In vivo. Next, 1 3 10
4 PFU of the viruses were inoculated
into mice to determine pathogenicity and viral growth in
vivo. Body weights were monitored for up to 8 d after
infection. The WH N66S virus caused the mice to start losing
weight at day 3, and weight loss continued in all WH N66S–
infected mice until day 8, resulting in 50% of the mice
succumbing to infection. The WH virus, while causing a slight
decrease in weight at day 7, did not cause signiﬁcant weight
loss, and all of the inoculated mice survived the infection
(Figure 3A). This difference in pathogenicity is mirrored by
the viral replication in the lungs. The WH N66S virus was
found to replicate to higher titers in the lungs and exhibited
peak virus titers 2 d earlier than the WH virus. WH N66S
replication in the lungs was signiﬁcantly higher than WH on
days 2, 5, and 8 after infection, with WH N66S replicating to
almost 100 times higher titers on each day (Figure 3B).
However, virus levels in the lung were equal on day 7,
suggesting that the continued weight loss of WH N66S–
infected mice is partially the result of increased cytokine
production in the lung. In addition, the high virus titer on
day 7 in WH-infected mice corresponds to the mild weight
Figure 2. In Vitro Growth Curve of Recombinant Viruses
(A) MDCK cells were inoculated at an MOI of 0.1 and 0.001, and virus
growth of WH and WH N66S was assessed at the time points indicated.
The figure is representative of three similar experiments.
(B) MDCK cells were inoculated at an MOI of .01 and .001, and virus
growth of r1918 and r1918 S66N was assessed at the time points
indicated.
doi:10.1371/journal.ppat.0030141.g002
Figure 3. Contribution of PB1-F2 N66S Mutation to Pathogenicity of
Recombinant Virus
(A) Mice were inoculated with 1 3 10
4 PFU of virus or PBS, and their
weights were recorded every day after infection.
(B) Virus titers from lung homogenates were measured from mice
infected with WH or WH N66S virus at days 1, 2, 3, 5, 7, and 8 after
inoculation. Error bars represent 1 standard deviation.
doi:10.1371/journal.ppat.0030141.g003
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Mutation in PB1-F2 Increases Virulenceloss seen in Figure 2B. WH N66S–infected mice exhibited
slower viral clearance with persisting high viral titers, whereas
the WH virus was cleared more effectively from the lung, with
3 out of 4 mice completely clearing the virus by day 8 (Figure
3B). Increased viral load and slowed viral clearance during
WH N66S infection could suggest an impaired cellular
immune response.
The 1918 pandemic virus contains an S at position 66 in
PB1-F2 corresponding to increased virulence as seen in the A/
Hong Kong/483/97 virus. To examine this aa in the context of
a fully reconstructed 1918 virus, a single aa change was made
(S66N) in PB1-F2 without changing the aa sequence of PB1.
To evaluate the virulence and pathogenicity of the 1918 S66N
mutant virus, the morbidity (measured by weight loss), virus
replication, and LD50 titers were determined in BALB/c mice
and compared with a group of animals infected with wild-
type 1918 virus, previously shown to be highly lethal in mice
[28].
As shown in Figure 4A, mice infected with doses of 10
3,1 0
4,
10
5, and 10
6 PFU of the wild-type 1918 virus began to lose
weight within 3 d. The mice showed progressive signs of
illness, such as rufﬂed fur and listlessness during the ﬁrst week
of infection before succumbing to infection (LD50 ¼ 10
2.5)b y
day 10 after inoculation. In contrast to the highly virulent
wild-type 1918 virus infection, higher amounts of inoculating
virus (10
5 and 10
6 PFU) were required to cause severe disease
and weight loss among the mice infected with 1918 S66N
mutant virus (Figure 4B). Furthermore, the lethality was
substantially lower (LD50 ¼ 10
5.25), requiring 500 times more
virus than wild-type 1918 virus to kill mice. Infection of mice
with the 10
4 PFU of 1918 S66N mutant virus resulted in lung
virus titers, on days 2 and 3 after infection, that were at least
12-fold lower than those of mice infected with the same dose
of wild-type 1918 virus (Figure 4C).
Cytokine Dysregulation in the Lungs of Infected Mice
To better understand the increased pathogenicity in the
infected mice, we examined the levels of TNF-a and IFN-c in
the lungs. IFN-c levels were observed to be higher in mice
infected with WH N66S virus, especially at days 7 and 8 after
infection, when the levels were approximately two times
higher than the levels in the WH virus-infected mice (Figure
5A). Levels of TNF-a in the lung also showed signiﬁcant
differences late in infection. At days 7 and 8 after infection,
TNF-a levels in mice infected with WH N66S virus had a two
times higher increase over levels in WH-infected mice (Figure
5B).
Individual lung tissues were also collected on day 4 after
infection from 1918 virus–infected mice. A single timepoint
(day 4 after infection) was chosen because it was previously
determined that maximal lung cytokine/chemokine levels
occurred at this time among mice infected with highly
virulent inﬂuenza strains [27,28]. Tissues were homogenized
and lysates were assayed for cytokines by the Bioplex Protein
Array system. Determination of IL-1a, IFN-c, and TNF-a
levels demonstrated that these cytokines were produced
above their constitutive levels 4 d after infection with both
Figure 4. The Effect of the S66N Mutation on Pathogenicity in Mice
(A) Eight mice were inoculated with recombinant wt 1918 virus at 10
2,
10
3,1 0
4,1 0
5,o r1 0
6 PFU, and their weights were measured every day.
Average weights are represented in the graph.
(B) Eight mice were inoculated with recombinant 1918 S66N virus at
10
2,10
3,1 0
4,1 0
5,o r1 0
6 PFU, and their weights were measured every
other day. Average weights are represented in the graph.
(C) Effect of S66N mutation on mouse lung titers in r1918 virus. Virus
titers from lung homogenates were measured from 3 mice infected per
time point with r1918 or r1918 S66N virus at days 1, 2, 3, 6, 7, and 8 after
inoculation. Error bars represent 1 standard deviation.
doi:10.1371/journal.ppat.0030141.g004
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cytokines were detected at signiﬁcantly higher levels (p   0.5,
analysis of variance) in 1918 wild-type–infected than in 1918
S66N mutant–infected mice. Together, these data indicate
that PB1-F2 may play a role in immunomodulation, especially
later in infection during viral clearance.
Discussion
Previous studies by our lab have shown that PB1-F2
contributes to the pathogenesis of the inﬂuenza A virus
[20]. When expression of PB1-F2 was knocked out of a
moderately virulent virus in mice, there was a signiﬁcant loss
in pathogenicity, indicating that PB1-F2 plays an important
role in virulence [20]. In the present study, we show that a
single aa change in PB1-F2 from highly virulent viruses
increases pathogenicity in mice and modulates the immune
response. It has been proposed that PB1-F2 causes apoptosis
of immune cells, which may lead to decreased antigen
presentation and a decrease in the adaptive immune response
[17]. Humans infected with highly pathogenic viruses con-
sistently have decreased lymphocytes and impaired immune
response to inﬂuenza virus infection [4,8,10,21,29,30]. We
wondered if these effects could be caused in part by PB1-F2.
In this study, we provide evidence that PB1-F2 does
contribute to the high pathogenicity phenotype and that
the N66S mutation, also found in the 1918 H1N1 virus,
contributes to virulence in highly pathogenic viruses.
After aligning the PB1-F2 sequences from H5N1 viruses
that exhibited high- and low-pathogenicity phenotypes, a
single aa change was found to correlate with high pathoge-
nicity. The location of the N66S mutation also made it an
excellent candidate for affecting the proapoptotic function
of PB1-F2. Position 66 is in the a-helical structure of PB1-F2,
in the mitochondrial targeting sequence. The location of aa
66 in the C-terminal mitochondrial targeting sequence of the
protein could affect PB1-F2 interactions with ANT3 and
VDAC1, potentially increasing the induction of apoptosis by
PB1-F2 [19].
Recombinant A/WSN/33 viruses were created to speciﬁcally
examine the effects of the N66S mutation during viral
infection. The recombinant virus WH has decreased patho-
genesis in mice compared with that of A/WSN/33 (unpub-
lished data), likely due to the mismatched polymerase genes,
resulting in less efﬁcient replication in the host. The N66S
mutation within the PB1-F2 protein partially reversed this
attenuating effect.
Within a natural setting, the presence of a ‘‘virulent’’ PB1-
F2 may be important when inﬂuenza viruses cross species
barriers or when new pandemic strains are generated by
reassortment. In fact, the PB1 gene has been one of the
segments found to reassort to create the pandemic strains of
1957 and 1968, potentially giving these viruses a more
pathogenic PB1-F2 and thus a higher virulence [13]. It is
possible that the PB1-F2 protein could allow a newly
reassorted virus to replicate in a new host efﬁciently enough
to spread, and develop mutations to create a more efﬁcient
polymerase complex. In addition, inﬂuenza surveillance data
shows that in recent history (1970 onward), H3N2 infections
cause almost 14 times the number of inﬂuenza related deaths
than H1N1 infections and are associated with a higher
epidemic severity index (as measured by the rate of increase
Figure 5. Cytokine Levels in Lungs of Infected Mice
(A) IFN-c enzyme-linked immunosorbent assay was performed on lung
homogenates with four mice per time point for each virus and is
represented here in ng/ml. *p , .05.
(B) TNF-a enzyme-linked immunosorbent assay was performed on lung
homogenates with four mice per time point for each virus represented
here in ng/ml. *p , .05.
(C) Lung homogenates collected on day 4 after inoculation were
measured for the levels of IL-1b, IFN-c, and TNF-a using the Bioplex
Protein Array system. All error bars represent 1 standard deviation.
doi:10.1371/journal.ppat.0030141.g005
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Mutation in PB1-F2 Increases Virulencein pneumonia and inﬂuenza mortality) [31–33]. Interestingly,
recent H1N1 isolates contain a truncated PB1-F2, which
possibly plays a role in their decreased virulence [19,34]. The
mutation we investigate here is not currently found in recent
H5N1 isolates; however, it is possible for those viruses to
acquire the mutation either through the error-prone RNA
polymerase or through reassortment with a virus that
contains the N66S mutation.
The observation that the WH N66S virus grew to higher
titers in the lung and persisted at high titers for a longer time
than the WH virus supports the role of PB1-F2 in allowing for
increased replication. This may also explain the impairment
of viral clearance in the mice infected with WH N66S. In
addition, the 1918 wt virus showed higher lung titers and
slower viral clearance when compared with the 1918 S66N
virus. We suspect that the delay in viral clearance due to
expression of PB1-F2 protein may allow for prolonged viral
replication and development of irreversible pulmonary
immunopathology, the ﬁndings observed with highly patho-
genic inﬂuenza strains. CD8
þ T cells are mainly responsible
for viral clearance in the host, and it is possible that their
function could be impaired by PB1-F2 [35,36]. In support of
this, we observed that the WH N66S and wt 1918 viruses
caused a signiﬁcant increase in IFN-c and TNF-a cytokine
production over the WH and 1918 S66N viruses, respectively.
Whether this change in cytokine levels is through the direct
action of PB1-F2 or through its impact on viral replication in
the lung is difﬁcult to determine. However, the cytokine
dysregulation is of special interest because it has been
associated with both H5N1 and 1918 H1N1 virus infections.
In previous studies, cytokine dysregulation was associated
with high virulence and death in animal models [29,37]. Our
study supports these ﬁndings and suggests that PB1-F2 could
be one of the factors contributing to the cytokine dysregu-
lation seen in H5N1 virus–infected patients and 1918 H1N1
virus–infected animals [4,37].
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